Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept
- First Online:
- Cite this article as:
- Amar, J., Serino, M., Lange, C. et al. Diabetologia (2011) 54: 3055. doi:10.1007/s00125-011-2329-8
- 2.5k Downloads
Evidence suggests that bacterial components in blood could play an early role in events leading to diabetes. To test this hypothesis, we studied the capacity of a broadly specific bacterial marker (16S rDNA) to predict the onset of diabetes and obesity in a general population.
Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) is a longitudinal study with the primary aim of describing the history of the metabolic syndrome. The 16S rDNA concentration was measured in blood at baseline and its relationship with incident diabetes and obesity over 9 years of follow-up was assessed. In addition, in a nested case–control study in which participants later developed diabetes, bacterial phylotypes present in blood were identified by pyrosequencing of the overall 16S rDNA gene content.
We analysed 3,280 participants without diabetes or obesity at baseline. The 16S rDNA concentration was higher in those destined to have diabetes. No difference was observed regarding obesity. However, the 16S rDNA concentration was higher in those who had abdominal adiposity at the end of follow-up. The adjusted OR (95% CIs) for incident diabetes and for abdominal adiposity were 1.35 (1.11, 1.60), p = 0.002 and 1.18 (1.03, 1.34), p = 0.01, respectively. Moreover, pyrosequencing analyses showed that participants destined to have diabetes and the controls shared a core blood microbiota, mostly composed of the Proteobacteria phylum (85–90%).
16S rDNA was shown to be an independent marker of the risk of diabetes. These findings are evidence for the concept that tissue bacteria are involved in the onset of diabetes in humans.
KeywordsAbdominal adiposity Microbiota Obesity 16S rDNA gene
Data from an Epidemiological Study on the Insulin Resistance Syndrome
Operational taxonomic diversity unit
The incidence of diabetes, in developed and emerging countries, has reached epidemic proportions . A body of evidence demonstrates that the intestinal microbiota, which correspond to the overall bacterial community present in the intestine, play a role in the onset of metabolic disease [2, 3, 4]. The causal role of the intestinal microbiota in weight gain has been demonstrated in animal models . In humans, obesity is associated with changed phylum levels in the gut microbiota . In addition, the role of bacterial components in blood has also been demonstrated: thus, mice chronically infused with a low dose of lipopolysaccharides developed inflammation and diabetes . Importantly, the plasma lipopolysaccharides concentration has been found to predict the onset of diabetes . From these data, we hypothesised that the presence of a blood microbiome could be one of the initial steps leading to diabetes and obesity. To test this hypothesis, we investigated whether the 16S rDNA concentration in blood could be a marker of the risk of diabetes and obesity in a large general population. We studied this gene as it is highly conserved between different species of bacteria and is hence considered to be a marker of the overall microbiota . Moreover, by pyrosequencing the overall 16S rDNA gene population in blood, we determined the profile of bacteria present in individuals who were destined to develop diabetes versus those present in controls.
Study overview Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) is a longitudinal cohort study of 5,212 adults aged 30 to 65 years at baseline; the primary aim of the study was to describe the natural history of the metabolic syndrome . Participants were recruited between 1994 and 1996 from volunteers insured by the French national social security system in ten social security health examination centres. All participants gave written informed consent and the study protocol was approved by the Comité Consultatif de Protection des Personnes pour la Recherche Biomédicale of the Hôpital Bicêtre (Paris, France). Participants were clinically and biologically evaluated at inclusion and at follow-up visits in years 3, 6 and 9. We measured the baseline 16S rDNA concentration in individuals without diabetes (defined by treatment for diabetes or fasting plasma glucose ≥ 7.0 mmol/l) or obesity (BMI ≥ 30 kg/m2) at baseline and in those who had a known diabetes status at the year 9 examination. We excluded those who were likely to have a current infection (C-reactive protein > 10 mg/l, abundant leucocyturia) or who were taking antiviral therapy.
Weight and height were measured in lightly clad participants and BMI was calculated. Waist circumference, i.e. the smallest circumference between the lower ribs and the iliac crests, was also measured. The examining physician noted the existence of a family history of diabetes, and treatments for diabetes and hypertension were recorded. Hypertension was defined as a systolic/diastolic blood pressure of at least 140/90 mmHg or taking antihypertensive medication. Smoking habits were documented in a questionnaire filled in by the participants. Central adiposity was defined as a waist circumference ≥102 cm in men and ≥88 cm in women, while high fasting glucose was defined as ≥ 6.1 mmol/l .
Blood was drawn after a 12 h fast. The methods used for biological analyses, except for bacterial DNA preparation and analysis, have been described elsewhere .
Bacterial DNA preparation
DNA was extracted from peripheral blood leucocytes using a classical phenol/chloroform extraction method followed by alcohol precipitation (ice-cold 70% alcohol by vol.). Air-dried DNA was resuspended in TRIS EDTA and stored at −80°C before use at a concentration of 1 μg/μl [9, 10]. It is noteworthy that this method did not use glass microbeads to increase the efficiency of bacterial DNA extraction, as commonly done in current methods. The reason for this was that isolation of bacterial DNA was not the goal of the work at the time of the sample preparation. However, despite this important technical difference, we succeeded in amplifying 16S rDNA from blood. To validate the difference between both extraction procedures, we extracted total blood DNA in the presence or absence of microbeads. The efficacy of bacterial DNA extraction, as assessed by 16S rDNA quantitative PCR amplification, was ten times greater when using microbeads. Although the absolute value of the bacterial DNA concentration was higher, the proportion between samples remained the same.
Quantification of 16S rDNA
The total DNA concentration was determined using a broad-range assay kit (Quant-iT dsDNA; Life Technologies, Villebon-sur-Yvette, France). The mean concentration ± SD was 121.1 ± 208.3 ng/μl. Each sample was diluted tenfold in TRIS buffer EDTA. The DNA was amplified by real-time PCR (Life Technologies) in optical-grade 96-well plates. The PCR reaction was performed in a total volume of 25 μl using a master mix (Power SYBR Green PCR; Life Technologies) containing 300 nmol/l of each of the universal forward and reverse primers for Eubact: forward 5′-TCCTACGGGAGGCAGCAGT-3′ and reverse 5′-GGACTACCAGGGTATCTAATCCTGTT-3′. The reaction conditions for amplification of DNA were 95°C for 10 min, and 35 cycles at 95°C for 15 s and at 60°C for 1 min. The amplification step was followed by a melting curve step according to the manufacturer’s instructions (from 60°C to 90°C) to determine the specificity of the amplification product obtained. The amount of amplified DNA was determined using a 16S rDNA standard curve obtained by real-time PCR from dilutions ranging from 0.001 to 10 ng/μl of E. coli BL21 DNA.
Identification of bacterial sequences
This sub-study included 14 participants with incident diabetes at year 9, but who had been at low risk of diabetes at baseline, having been non-smokers with a waist perimeter of < 85 cm for men and < 75 cm for women. These 14 participants were matched for age (±3 years), sex, waist circumference (±3 cm) and fasting blood glucose (±0.3 mmol/l) with 28 control participants who remained free of diabetes over the entire follow-up period. The V1–V2 variable region of the 16S rDNA gene was amplified by PCR for each participant, and amplicons from case and control participants were pooled separately after size verification by 2% agarose gel electrophoresis. Each pool was assigned to specific multiplex identifiers (MIDs) that were used as tags. These two pools of amplicons were pyrosequenced using a genome sequencer (454 Life Sciences; Branford, CT, USA) on a multiplexed pyrosequencing run (GS FLX-Ti; Life Technology). Sequences were binned for removal of pyrosequencing MIDs and PCR primers (forward: AG-AGT-TTG-ATC-MTG-GCT-CAG; reverse: GC-TGC-CTC-CCG-TAG-GAG-T) [2, 3]. Meta_RNA software, designed for the identification of 16S rRNA sequences based on hidden Markov models, was further applied to select prokaryotic 16S rRNA sequences . The resulting 16S rRNA sequences were assigned to taxonomies using mothur software  and the SILVA reference taxonomic outline .
Of the 919,095 and 768,245 sequence reads recovered for case and control participants respectively, ∼30% were removed by initial quality filters. A de-noising step was performed to remove most of the common sequencing errors encountered with the 454 platform by clustering chimeric sequences as well as reads that were most likely to have been derived from the same sequence.
For statistical analysis, in order to carry out parametric tests, the 16S rDNA concentrations were log-transformed, as the distribution was skewed (as were levels of triacylglycerol and insulin). The characteristics of the participants who did and did not have incident diabetes over follow-up are shown and compared by t and χ² tests. Note that log-transformed 16S rDNA concentrations were compared statistically. For incident diabetes and abdominal adiposity, logistic regression was used to calculate the standardised odds ratios and 95% CIs for an increase of one SD of baseline 16S rDNA concentration as a continuous variable (logarithm). Adjustments were made for sex, baseline age, family history of diabetes, hypertension, waist circumference, BMI, smoking status and fasting plasma glucose. The relationship with 16S rDNA concentration was linear, as an additional squared term was not significant. ORs were also calculated over risk factor strata. The C statistic was used to quantify the discriminative ability of 16S rDNA and that of various risk factors for diabetes. SAS versions 9.1 and 9.2 (Cary, NC, USA) were used for statistical analysis.
Socio-demographic and other characteristics of study population
Women, n (%)
Diabetes in family, n (%)
Current smoker, n (%)
Hypertension, n (%)a
Education level, n (%)b
High school or higher
Laboratory and other characteristics of study population
Mean ± SD
Mean ± SD
47 ± 10
51 ± 9
23.8 ± 2.8
25.8 ± 2.5
88 ± 8
92 ± 7
75 ± 8
83 ± 7
5.23 ± 0.49
6.07 ± 0.55
5.83 ± 0.51
40.19 ± 5.61
Total cholesterol (mmol/l)
5.69 ± 0.97
6.01 ± 1.10
1.06 ± 0.65
1.63 ± 1.42
41.80 ± 21.40
61.16 ± 35.67
83.35 ± 25.73
79.01 ± 32.59
0.97 ± 0.45
1.41 ± 0.76
2.93 ± 0.61
3.15 ± 0.71
Leucocyte count (g/l)a, c
63 ± 17
67 ± 20
16S rDNA gene (ng/μl)
0.13 ± 0.27
0.15 ± 0.25
Log 16S rDNA gene (ng/μl)
−2.72 ± 1.05
−2.53 ± 1.00
Correlation coefficients between blood bacterial DNA gene concentration and other biological variables
Fasting blood glucose (mmol/l)
Leucocyte count (g/l)
Prediction of diabetes and abdominal adiposity
Adjusted ORs (95% CI) of incident diabetes for 1 SD of log (16S rDNA gene concentration) in the overall population and in various strata
Incident diabetes (n)
Median age (years)
High school or higher
Diabetes in family
High fasting glucose
The 16S rDNA concentration also predicted the presence of abdominal adiposity at the end of 9 years, after adjustment for confounders, with a standardised OR of 1.18 (95% CI 1.03, 1.34; p = 0.01).
Identification of blood bacteria phyla in participants with incident diabetes
We show, for the first time, that the blood concentration of a bacterial gene predicts the onset of diabetes, particularly 6 to 9 years after baseline, and also predicts abdominal adiposity in a large sample of non-obese participants from a general population. We found that more than 90% of this bacterial DNA belonged to the Proteobacteria phylum.
The involvement of inflammation in the development of insulin resistance [14, 15, 16] and the pro-inflammatory effects of bacterial components present within tissues  suggest that the role played by tissue bacteria in relation to diabetes and its complications should be explored. Indeed, experimental data have already linked the metabolic syndrome with gut microbiota and innate immunity against infectious diseases [3, 4]. We [4, 17, 18] and others  have demonstrated the influence of gut microbiota on metabolic disease in animal models. Consistently, in humans, periodontitis, a chronic gram-negative infectious disease of the oral cavity, has been associated with the metabolic syndrome [19, 20, 21, 22, 23]. In line with these data, the longitudinal study reported here provides for the first time evidence of the involvement of tissue microbiota in the development of diabetes in humans.
These epidemiological data also provide some insight into the mechanisms of action of the microbiota. Indeed, although no difference was observed in blood microbiota composition in participants destined to develop diabetes and in controls, possibly because of a lack of statistical power, we did establish the predominance of proteobacteria, which represent 90% of overall microbiota. In this respect, the role of lipopolysaccharides, a major component of proteobacteria, in the onset of diabetes has already been demonstrated [3, 5]. Interestingly, in faeces, this phylum is in the minority, since Bacteroidetes and Firmicutes are the most predominant phyla , suggesting selectivity of the filtering mechanism, which allows only some bacteria to be present in the blood . From these data, it seems possible that proteobacteria play a role in the onset of metabolic diseases. Our results show at baseline a negative correlation between bacterial DNA levels and fasting blood glucose. At this stage, we cannot rule out a transitory improvement in insulin sensitivity in the early phase of metabolic infection, as shown in an experimental model of gram-negative sepsis in healthy humans [25, 26]. This could be due to the release of nitric oxide during latent infection, which would in turn improve insulin sensitivity [27, 28]. On the other hand, the exclusion of patients with treated or non-treated diabetes at baseline, i.e. participants in whom bacteraemia would already have had a deleterious influence on glucose metabolism, is more likely to have contributed to this association. Obviously, the present study is observational in nature and thus cannot demonstrate the causative role played by blood microbiota in the onset of diabetes. Indeed, the blood bacterial DNA burden may only represent an innocent bystander in the disease process. Moreover, these results are preliminary and need to be replicated in other longitudinal data sets.
In conclusion, our results show for the first time that blood microbiota are a marker of the risk of diabetes and abdominal adiposity in a general population. These findings establish evidence for the concept of an involvement of tissue bacteria in the onset of diabetes in humans.
This work was funded by the Agence Nationale de la Recherche (French national research agency) (to R. Burcelin) and by the Société Francophone de Diabète (to B. Balkau). The D.E.S.I.R. study has been supported by Inserm contracts with CNAMTS, Lilly, Novartis Pharma and sanofi-aventis; by Inserm (Réseaux en Santé Publique, Interactions entre les déterminants de la santé, Cohortes Santé TGIR 2008), the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Société Francophone du Diabète, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon.
JA co-designed the study, contributed to the statistical analyses and interpretation of data, and wrote the first draft of the manuscript. RB co-designed the study, conducted the biological analyses, and contributed to interpretation of data and the writing of the manuscript. BB (principal investigator of the DESIR study) conducted statistical analyses, and contributed to the interpretation of data and to the writing of the manuscript. MS, LP and PK carried out biological analyses, and contributed to the interpretation of data and to the writing of the manuscript. CL carried out statistical analyses, and contributed to interpretation of data and to the writing of the manuscript. CC carried out biological analyses, and contributed to interpretation of data and to the writing of the manuscript. JI carried out bioinformatic analyses, and contributed to interpretation of data and to the writing of the manuscript. SM, PL, CK, JM, OB and JD contributed to pyrosequencing analyses, interpretation of data and the writing of the manuscript. MC and MAC contributed to the interpretation of data and the writing of the manuscript. MM created the DNA collection of the D.E.S.I.R. study and contributed to interpretation of data and to the writing of the manuscript. OL researched data, and contributed to interpretation of data and the writing of the manuscript. All authors approved the final version of the manuscript to be published.
Duality of interest
J. Amar, R. Burcelin and M. Courtney are major shareholders of VAIOMER, a biotechnology company in the field of metabolic diseases. The remaining authors declare that they have no duality of interest associated with this manuscript.